吕宁

一、基本情况

主任医师、医学博士、硕士生导师

门诊时间：越秀院区：周二上午

专业特长：擅长肝癌微创介入治疗、免疫靶向治疗等综合治疗，主要开展肝动脉灌注化疗HAIC、栓塞化疗TACE、消融等局部治疗，及局部联合免疫靶向全身治疗。

学术成绩：在肿瘤多学科综合诊疗MDT理念下，开展肝癌微创介入治疗临床和转化研究，主要创新性成果介入肝动脉灌注化疗HAIC技术被国家卫健委官方指南《原发性肝癌诊疗指南CNLC》及中国抗癌协会CACA、中国临床肿瘤学会CSCO等推荐在临床一线治疗中应用；主持国家自然科学基金2项；以实际第一或通讯作者发表论文多篇，主要包括JCO、Nat Commun、Gut、J Hepatol等，其中ESI高被引论文3篇。

二、教育及工作经历

2025.12 – 至今，中山大学肿瘤防治中心，微创介入治疗科，主任医师

2025.09 – 2026.02，国家肿瘤区域医疗中心-中山大学附属肿瘤医院甘肃医院，介入治疗科，执行主任（中肿援甘第八批派驻期间）

2020.12 – 2025，中山大学肿瘤防治中心，微创介入治疗科，副主任医师

2015.12 – 2020，中山大学肿瘤防治中心，微创介入治疗科，主治医师

2012.12 – 2015，中山大学肿瘤防治中心，微创介入治疗科，医师

三、学术兼职

1. 中国医师协会-CCI “中国介入新锐”（2022）

2. 中国抗癌协会CACA肿瘤介入学专业委员会-委员（第六届）

3. 中国抗癌协会CACA肿瘤微创治疗专业委员会-委员（第六届）

4. 中国临床肿瘤学会CSCO肝癌专家委员会-委员（第三届）

5. 广东省抗癌协会肿瘤标志专业委员会-常务委员（第二届）

6. 广东省医学会肝癌分会-委员（第三届）

7. 广东省医学会放射防护学分会-委员（第四届）

四、主持科研项目

1. 国家自然科学基金-面上项目（2025-2028）

2. 国家自然科学基金-青年基金C类（2020-2022）

3. 广东省自然科学基金-面上项目（2021-2023）

4. 中山大学临床医学研究-5010计划项目（2017-2018）

五、代表性论著

（一）第一或通讯作者

1. Lyu N(第一作者), Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao Ming. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Journal of Clinical Oncology. 2022 Feb 10;40(5):468-480.（ESI高被引论文）

2. He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, Chen Q, Hu Y, Chen H, Wang X, Jiang X, Xia X, Zhao M, Lyu N(最后通讯). Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. Nature Communications. 2024 Feb 26;15(1):1754.（ESI高被引论文）

3. Lyu N(第一作者), Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology. 2018 Jul;69(1):60-69.（ESI高被引论文）

4. Lyu N(第一作者), Lin Y, Kong Y, Zhang Z, Liu L, Zheng L, Mu L, Wang J, Li X, Pan T, Xie Q, Liu Y, Lin A, Wu P, Zhao M. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut. 2018 Feb;67(2):395-396.

5. Wu X, Yi J, Zhang Y, Wang J, Li L, Zeng J, Ding K, Fan Y, Liu X, Zhu Z, Yuan D, Ning S, Zhang J, You Y, Xu J, Guo R, Chen M, Zhao M, Lyu N(最后通讯). Influence of metabolic dysfunction-associated steatotic liver disease and metabolic risk factors on immunotherapy outcomes in hepatocellular carcinoma with chronic hepatitis B. Hepatobiliary Surgery and Nutrition. 2025

6. Lyu N(第一作者), Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer. 2022 Feb;162:76-98.

7. Lyu N(第一作者), Kong Y, Li X, Guo N, Lai J, Li J, Zhao M. Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial. Journal of the American College of Radiology. 2022 Jan;19:61-70.

8. Lv N(第一作者), Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. European Radiology. 2016 Oct;26(10):3492-9.

9. Lyu N(第一作者), Kong Y, Pan T, Mu L, Sun X, Li S, Deng H, Lai J, Zhao M. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia. 2019;36(1):1003-1011.

10. Lyu N(第一作者), Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. Journal of Vascular and Interventional Radiology. 2019 Mar;30(3):349-357.

（二）共同第一或通讯作者

1. Zhang Y, Wu X, Yi J, Xu J, Zhang Y, Lyu N(共通/倒2), Zhao M. Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2025 Apr 22;14(5):620-637.

2. Zhong S, Yi J, Chen S, Mo X, Chen Q, Guo W, Jiang X, Mu L, Hu Y, Wang J, Song Y, Xu J, Tan G, Shi M, Chen M, Lyu N(共通/倒2), Zhao M. Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus. Hepatology International. 2025 Feb 11. doi: 10.1007/s12072-025-10777-8.

3. Chen QF, Chen S, Yi JZ, Wang JL, Zhong SX, Jiang XY, Hu Y, Tan GJ, Xu J, Lyu N(共通/倒2), Zhao M. Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation. American Journal of Gastroenterology. 2024 Oct 1;119(10):2052-2060.

4. Yi JZ, Zhu ZJ, Liu GW, Zhang YM, Xu J, Wu XT, Ding K, Liu JC, Zhang KF, Jiang XY, Chen QF, Hu Y, Chen S, Zhong SX, Wang JL, Lyu N(共通/倒2), Zhao M. Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study. Hepatology Research. 2024 Jun;54(6):575-587.

5. Chen QF, Chen S, Chen M, Lyu N(共通/倒2), Zhao M. Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate. Journal of Clinical and Translational Hepatology. 2024 Mar 28;12(3):298-304.

6. Chen QF, Lyu N(共一/第2), Wang X, Jiang XY, Hu Y, Chen S, Zhong SX, Huang ZL, Chen M, Zhao Ming. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. International Journal of Surgery. 2023 Sep 4;109(12):3929–39.

7. Li S, Lyu N(共一/第2), Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. Journal of Vascular and Interventional Radiology. 2021 Sep;32(9):1267-1276.

8. Deng H, Kan A, Lyu N(共一/第3), He M, Huang X, Qiao S, Li S, Lu W, Xie Q, Chen H, Lai J, Chen Q, Jiang X, Liu S, Zhang Z, Zhao M. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2021 Jun;9(6):e002305.

9. Chen QF, Liu S, Lyu N(共一/第3), Jia Z, Chen M, Zhao M. Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. Journal of Vascular and Interventional Radiology. 2021 Nov;32(11):1548-1557.

10. Deng H, Kan A, Lyu N(共一/第3), Mu L, Han Y, Liu L, Zhang Y, Duan Y, Liao S, Li S, Xie Q, Gao T, Li Y, Zhang Z, Zhao M. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer. 2020 Jun;9(3):338-357.

（三）参与发表肝癌介入治疗专家共识

1. Zhao Ming, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, Fan WJ, Li HL, Yang JJ, Chen XM, Xu LF, Zhang YW, Zhu KS, Sun JH, Li JP, Jin Y, Yu HP, Duan F, Xiong B, Yin GW, Lin HL, Ma YL, Wang HM, Gu SZ, Si TG, Wang XD, Zhao C, Yu WC, Guo JH, Zhai J, Huang YH, Wang WY, Lin HF, Gu YK, Chen JZ, Wang JP, Zhang YM, Yi JZ, Lyu N（主要撰写作者）. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatology International. 2024 Feb;18(1):4-31. （中国肝细胞癌肝动脉灌注化疗专家共识）

六、获奖及荣誉

中国医师协会介入医师分会CCI“中国介入新锐”（2022）

更新时间：2026.2.26